Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
McKesson
Express Scripts
Harvard Business School
McKinsey

Last Updated: December 3, 2022

CLINICAL TRIALS PROFILE FOR XELJANZ XR


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Xeljanz Xr

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01932372 ↗ Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis Completed Pfizer 2013-07-26 The objective of this Surveillance is to verify the following subject matters concerning Tofacitinib (Xeljanz) under general practice. 1) Occurrence of adverse reactions, factors that may potentially affect safety and efficacy 2) Long-term safety (particularly, malignant tumors and serious infections) and efficacy Occurrences of malignant tumors and serious infections will be compared with a control group.
NCT02157012 ↗ Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Showa Inan General Hospital Phase 4 2014-05-01 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02157012 ↗ Evaluation of the Condition of Rheumatoid Arthritis After Treatment Recruiting Shinshu University Phase 4 2014-05-01 To examine the safety and effectiveness after Xeljanz treatment in rheumatoid arthritis patients
NCT02299297 ↗ Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Completed Locks of Love Phase 2 2015-01-01 This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator.
NCT02299297 ↗ Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis Completed Columbia University Phase 2 2015-01-01 This is an open-label pilot study of tofacitinib taken daily for 6 months in the treatment of moderate to severe AA, and alopecia totalis or universalis, followed by 6 months follow-up off drug to assess the incidence and timing of recurrence of disease or documentation of delayed response to treatment. There will be the option of increasing the treatment duration up to an additional 6 months beyond the initially scheduled 6 months of treatment, if clinically indicated, and at the discretion of the investigator.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Xeljanz Xr

Condition Name

Condition Name for Xeljanz Xr
Intervention Trials
Rheumatoid Arthritis 9
Alopecia Areata 4
Psoriatic Arthritis 3
Ulcerative Colitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Xeljanz Xr
Intervention Trials
Arthritis 12
Arthritis, Rheumatoid 9
Alopecia Areata 4
Alopecia 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Xeljanz Xr

Trials by Country

Trials by Country for Xeljanz Xr
Location Trials
United States 35
China 6
Mexico 6
Spain 5
Canada 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Xeljanz Xr
Location Trials
Florida 3
Ohio 3
Pennsylvania 3
California 3
Louisiana 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Xeljanz Xr

Clinical Trial Phase

Clinical Trial Phase for Xeljanz Xr
Clinical Trial Phase Trials
Phase 4 8
Phase 3 4
Phase 2 7
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Xeljanz Xr
Clinical Trial Phase Trials
Recruiting 14
Completed 9
Not yet recruiting 3
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Xeljanz Xr

Sponsor Name

Sponsor Name for Xeljanz Xr
Sponsor Trials
Pfizer 9
University of Nebraska 2
Stanford University 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Xeljanz Xr
Sponsor Trials
Other 36
Industry 17
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Dow
Express Scripts
McKinsey
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.